Glaukos (GKOS) Stock Price, News & Analysis

Company Overview

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions. Its iDose TR implant delivers a controlled release of travoprost directly into the eye over several months, aiming to reduce patient compliance issues associated with daily eye drops. Through its acquisition of Avedro in 2019, Glaukos also offers corneal cross-linking technologies and other phototherapeutic solutions for the treatment of keratoconus and corneal ectasia, broadening the company’s presence in the ophthalmic market.

Founded in 1998 and headquartered in San Clemente, California, Glaukos has built a global commercial organization serving surgeons and patients in North America, Europe, Asia Pacific and the Middle East. The company combines direct sales teams in key markets with strategic distribution partnerships to support product training, clinical research and market access. Glaukos continuously invests in research and development to advance its pipeline of minimally invasive ophthalmic therapies.

Leadership at Glaukos is headed by President and Chief Executive Officer Thomas Burns, who joined the company in 2018 and has overseen its expansion into new therapeutic areas and geographies. Under his guidance, Glaukos remains committed to improving patient outcomes through novel, less-invasive treatments that aim to preserve vision and enhance quality of life for individuals living with glaucoma and other eye diseases.

Key Stats

• Today's Range: $172.98 to $180.64
• 50-Day Range: $137.46 to $189.72
• 52-Week Range: $73.16 to $191.62
• Volume: 83,790 shs
• Average Volume: 850,006 shs
• Market Capitalization: $10.67 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $178.08
• Consensus Rating: Moderate Buy

Glaukos Stock Analysis - MarketRank™

Glaukos scored higher than 30% of companies evaluated by MarketBeat, and ranked 756th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Glaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for Glaukos is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Glaukos has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Glaukos are expected to grow in the coming year, from ($0.32) to $0.51 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Glaukos is -55.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Glaukos is -55.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Glaukos has a P/B Ratio of 15.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.12% of the float of Glaukos has been sold short.

Short Interest Ratio / Days to Cover

Glaukos has a short interest ratio ("days to cover") of 5.21.

Change versus previous month

Short interest in Glaukos has recently increased by 8.95%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Glaukos does not currently pay a dividend.

Dividend Growth

Glaukos does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.69

News Sentiment

Glaukos has a news sentiment score of 1.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Glaukos this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for GKOS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,600,006.00 in company stock.

Percentage Held by Insiders

5.90% of the stock of Glaukos is held by insiders.

Percentage Held by Institutions

99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 9/08/2026
• Wells Fargo 21st Annual Healthcare Conference: 9/09/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:GKOS
• CIK: 1192448
• Web: www.glaukos.com
• Phone: (949) 367-9600
• Fax: 949-367-9984
• Employees: 1,094
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Glaukos: $178.08
• High Price Target: $215.00
• Low Price Target: $138.00
• Potential Upside/Downside: -0.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.79
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$187.69 million
• Net Margins: -30.68%
• Pretax Margin: -31.47%
• Return on Equity: -6.37%
• Return on Assets: -4.78%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 5.04
• Quick Ratio: 4.46

Sales & Book Value

• Annual Sales: $507.44 million
• Price / Sales: 20.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.42 per share
• Price / Book: 15.73

Miscellaneous

• Outstanding Shares: 58,980,000
• Free Float: 55,504,000
• Market Cap: $10.60 billion
• Optionable: Optionable
• Beta: 0.76